Market Cap 327.65B
Revenue (ttm) 56.33B
Net Income (ttm) 4.28B
EPS (ttm) N/A
PE Ratio 18.06
Forward PE 15.10
Profit Margin 7.59%
Debt to Equity Ratio 47.80
Volume 12,158,100
Avg Vol 7,258,350
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 16%
Beta 0.50
Analysts Strong Sell
Price Target $208.88

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
ZacksResearch
ZacksResearch Jun. 20 at 7:59 PM
$LLY or $ABBV: Which Pharma Giant Should You Bet On? 💊💥 Eli Lilly's overall business expects a 32% revenue growth for 2025, fueled by its diverse drug portfolio, including GLP-1 drugs, Mounjaro and Zepbound. Yet, AbbVie, with its strong Skyrizi and Rinvoq sales and a cheaper valuation, looks like a safer bet for short-term investors, boasting a 3.5% dividend yield and projected mid-single-digit revenue growth in 2025. 📈💰 Discover the full comparison and insights here 👉 https://www.zacks.com/commentary/2519897/lly-vs-abbv-which-pharma-powerhouse-is-the-better-bet?cid=sm-stocktwits-2-2519897-body&ADID=SYND_STOCKTWITS_TWEET_2_2519897_BODY
1 · Reply
swingingtech
swingingtech Jun. 20 at 4:00 PM
$DAL $ABBV $USB https://wallstreetwaves.com/daily-dividend-update-delta-air-lines-abbvie-u-s-bancorp-guaranty-bancshares-lennar/
0 · Reply
ripztrip
ripztrip Jun. 20 at 3:32 PM
$CAPR shorts here are SO devious!!!! jeez. TRYING to do whatever they can to keep it BELOW 10?? this going to be approved shortly. marked. KNOW what you own!!!! This way a hit and run today with a lot of people with stop losses pushed out for no reason..... $SRPT $PFE $ABBV $GILD
0 · Reply
ZacksResearch
ZacksResearch Jun. 20 at 2:43 PM
$LLY vs. $ABBV — Growth rocket or value sleeper? 💥🧪 LLY’s obesity drugs are driving explosive growth, but ABBV’s valuation and pipeline could offer a more stable near-term payoff. See the full risk/reward breakdown here 👉 https://www.zacks.com/stock/news/2519897/lly-vs-abbv-which-pharma-powerhouse-is-the-better-bet?cid=sm-stocktwits-2-2519897-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2519897_TEASER
0 · Reply
Tat2doc
Tat2doc Jun. 20 at 11:43 AM
$LLY $GSK $MRK $ABBV $PFE it’s a big pharma Friday! 🚀 Bunker bust my butt! Money talks and bs walks!
0 · Reply
ripztrip
ripztrip Jun. 20 at 1:36 AM
$CAPR https://x.com/MarbanLab/status/1935680099501985990 $SRPT $PFE $ABBV $GILD
0 · Reply
onestudy
onestudy Jun. 19 at 12:58 AM
$CPHI A major investment research firm named CPHI as one of the few pharmaceutical companies licensed to manufacture Cerebroprotein Hydrolysate — a CNS (central nervous system) drug used to treat Alzheimer’s disease, stroke, Parkinson’s-related dementia, and brain injury. I was surprised to learn this drug is actually derived from pig brain. I didn’t expect that — but it turns out many major pharma companies also use animal-derived ingredients. For example: 🐷 $PFE produces blood thinners (heparin) from pig intestines 🧬 $ABBV uses pig pancreas enzymes to treat pancreatic disorders 💉 $NVO developed early insulin treatments from pig and cow pancreases 🧫 $BMY uses animal cells in biologics and antibody drug development Animal-based biotech is more common than people think and CPHI is part of that landscape.
0 · Reply
Alice_in_Dollarland
Alice_in_Dollarland Jun. 18 at 5:11 PM
$ELTP Pharmaceutical company specializing in a broad range of generic medications, including Oxycodone, Percocet, and Vyvanse. Next earnings report set for the end of THIS month and will show revenue for the launch of these new releases. New working facility HERE in the states. Positive study results for new generic anticoagulant drug. $ABBV $LLY $TEVA
4 · Reply
OptionSamurai
OptionSamurai Jun. 18 at 2:55 PM
$ABBV appears in our scan that looks for calls that will explode if the stock goes to analyst target. Analysts rating is BUY and the target price is 14.3% away📈. Call 190.0, 15-Aug-25 has: Max loss of 3.4% compared to holding shares and Breakeven is 5.4% away. If the stock hits the target, the call will profit 260% 🔥🔥🔥. 👉 Create your own scan here: https://bit.ly/3lR1xIP
0 · Reply
Iwannagofast1
Iwannagofast1 Jun. 18 at 2:55 PM
$ABBV same price as Jan ….just chill w this is the 401K forever
0 · Reply
Latest News on ABBV
I'm Buying Dividend Giants At Huge Discounts

Jun 20, 2025, 9:00 AM EDT - 1 day ago

I'm Buying Dividend Giants At Huge Discounts

BMY CVX OXY PFE SHEL SLB TTE


AbbVie Declares Quarterly Dividend

Jun 20, 2025, 8:00 AM EDT - 1 day ago

AbbVie Declares Quarterly Dividend


AbbVie's migraine drug meets main goal of late-stage study

Jun 18, 2025, 7:27 AM EDT - 3 days ago

AbbVie's migraine drug meets main goal of late-stage study


AbbVie says blood cancer drug fails late-stage trial

Jun 16, 2025, 9:12 AM EDT - 5 days ago

AbbVie says blood cancer drug fails late-stage trial


AbbVie: Margin Clarity, Dividend Durability Awaited

Jun 16, 2025, 5:05 AM EDT - 5 days ago

AbbVie: Margin Clarity, Dividend Durability Awaited


AbbVie Moves From Blockbuster Loss To Market Domination

Jun 16, 2025, 1:29 AM EDT - 5 days ago

AbbVie Moves From Blockbuster Loss To Market Domination


AbbVie's Post-Humira Strategy Is Paying Off For Investors

Jun 15, 2025, 7:11 AM EDT - 6 days ago

AbbVie's Post-Humira Strategy Is Paying Off For Investors


Bert's May 2025 Dividend Income Summary

Jun 3, 2025, 1:43 PM EDT - 17 days ago

Bert's May 2025 Dividend Income Summary

C CZNC KMI NSC O PG SBUX


Put Cash To Work: 2 Magnificent Dividends I'm Betting On

Jun 2, 2025, 10:00 AM EDT - 19 days ago

Put Cash To Work: 2 Magnificent Dividends I'm Betting On

RTX


Final Trades: JPMorgan, Meta, Abbvie and Gap

May 30, 2025, 4:20 PM EDT - 21 days ago

Final Trades: JPMorgan, Meta, Abbvie and Gap

META GAP JPM


AbbVie Partners with Chicago Cubs on "Striking Out Cancer"

May 30, 2025, 8:00 AM EDT - 22 days ago

AbbVie Partners with Chicago Cubs on "Striking Out Cancer"


Best Dividend Aristocrats For June 2025

May 27, 2025, 10:15 PM EDT - 24 days ago

Best Dividend Aristocrats For June 2025

ABT ADM ADP AFL ALB AMCR AOS


3 Stocks That Will Profit From Trump's Drug Price Cut

May 16, 2025, 1:08 PM EDT - 5 weeks ago

3 Stocks That Will Profit From Trump's Drug Price Cut

LLY NVO


Is It Time To Buy AbbVie Stock At $180?

May 16, 2025, 8:30 AM EDT - 5 weeks ago

Is It Time To Buy AbbVie Stock At $180?


US FDA approves AbbVie's drug for a type of lung cancer

May 14, 2025, 1:23 PM EDT - 5 weeks ago

US FDA approves AbbVie's drug for a type of lung cancer


ZacksResearch
ZacksResearch Jun. 20 at 7:59 PM
$LLY or $ABBV: Which Pharma Giant Should You Bet On? 💊💥 Eli Lilly's overall business expects a 32% revenue growth for 2025, fueled by its diverse drug portfolio, including GLP-1 drugs, Mounjaro and Zepbound. Yet, AbbVie, with its strong Skyrizi and Rinvoq sales and a cheaper valuation, looks like a safer bet for short-term investors, boasting a 3.5% dividend yield and projected mid-single-digit revenue growth in 2025. 📈💰 Discover the full comparison and insights here 👉 https://www.zacks.com/commentary/2519897/lly-vs-abbv-which-pharma-powerhouse-is-the-better-bet?cid=sm-stocktwits-2-2519897-body&ADID=SYND_STOCKTWITS_TWEET_2_2519897_BODY
1 · Reply
swingingtech
swingingtech Jun. 20 at 4:00 PM
$DAL $ABBV $USB https://wallstreetwaves.com/daily-dividend-update-delta-air-lines-abbvie-u-s-bancorp-guaranty-bancshares-lennar/
0 · Reply
ripztrip
ripztrip Jun. 20 at 3:32 PM
$CAPR shorts here are SO devious!!!! jeez. TRYING to do whatever they can to keep it BELOW 10?? this going to be approved shortly. marked. KNOW what you own!!!! This way a hit and run today with a lot of people with stop losses pushed out for no reason..... $SRPT $PFE $ABBV $GILD
0 · Reply
ZacksResearch
ZacksResearch Jun. 20 at 2:43 PM
$LLY vs. $ABBV — Growth rocket or value sleeper? 💥🧪 LLY’s obesity drugs are driving explosive growth, but ABBV’s valuation and pipeline could offer a more stable near-term payoff. See the full risk/reward breakdown here 👉 https://www.zacks.com/stock/news/2519897/lly-vs-abbv-which-pharma-powerhouse-is-the-better-bet?cid=sm-stocktwits-2-2519897-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2519897_TEASER
0 · Reply
Tat2doc
Tat2doc Jun. 20 at 11:43 AM
$LLY $GSK $MRK $ABBV $PFE it’s a big pharma Friday! 🚀 Bunker bust my butt! Money talks and bs walks!
0 · Reply
ripztrip
ripztrip Jun. 20 at 1:36 AM
$CAPR https://x.com/MarbanLab/status/1935680099501985990 $SRPT $PFE $ABBV $GILD
0 · Reply
onestudy
onestudy Jun. 19 at 12:58 AM
$CPHI A major investment research firm named CPHI as one of the few pharmaceutical companies licensed to manufacture Cerebroprotein Hydrolysate — a CNS (central nervous system) drug used to treat Alzheimer’s disease, stroke, Parkinson’s-related dementia, and brain injury. I was surprised to learn this drug is actually derived from pig brain. I didn’t expect that — but it turns out many major pharma companies also use animal-derived ingredients. For example: 🐷 $PFE produces blood thinners (heparin) from pig intestines 🧬 $ABBV uses pig pancreas enzymes to treat pancreatic disorders 💉 $NVO developed early insulin treatments from pig and cow pancreases 🧫 $BMY uses animal cells in biologics and antibody drug development Animal-based biotech is more common than people think and CPHI is part of that landscape.
0 · Reply
Alice_in_Dollarland
Alice_in_Dollarland Jun. 18 at 5:11 PM
$ELTP Pharmaceutical company specializing in a broad range of generic medications, including Oxycodone, Percocet, and Vyvanse. Next earnings report set for the end of THIS month and will show revenue for the launch of these new releases. New working facility HERE in the states. Positive study results for new generic anticoagulant drug. $ABBV $LLY $TEVA
4 · Reply
OptionSamurai
OptionSamurai Jun. 18 at 2:55 PM
$ABBV appears in our scan that looks for calls that will explode if the stock goes to analyst target. Analysts rating is BUY and the target price is 14.3% away📈. Call 190.0, 15-Aug-25 has: Max loss of 3.4% compared to holding shares and Breakeven is 5.4% away. If the stock hits the target, the call will profit 260% 🔥🔥🔥. 👉 Create your own scan here: https://bit.ly/3lR1xIP
0 · Reply
Iwannagofast1
Iwannagofast1 Jun. 18 at 2:55 PM
$ABBV same price as Jan ….just chill w this is the 401K forever
0 · Reply
ripztrip
ripztrip Jun. 18 at 2:28 PM
$CAPR What is expected at PPMD? Is there a livestream link to share? $SRPT $PFE $GILD $ABBV
0 · Reply
mikesterz7
mikesterz7 Jun. 18 at 1:58 PM
$ABBV 🚨 AbbVie’s Migraine Drug Yields Positive Outcome In Late-Stage Study Versus Topiramate
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 18 at 1:45 PM
AbbVie’s Migraine Drug Yields Positive Outcome In Late-Stage Study Versus Topiramate, But Fails To Draw Retail Cheer $ABBV $VTI $VOO https://stocktwits.com/news/equity/markets/abbvie-migraine-drug-yields-positive-outcome-in-late-stage-study-vs-topiramate/chls3L9RR23
0 · Reply
swingingtech
swingingtech Jun. 18 at 1:12 PM
$MSLC $BN $MASI $ABBV https://wallstreetwaves.com/unexpected-12-month-forecast-for-mslc-by-analysts/
0 · Reply
megan_foster
megan_foster Jun. 18 at 1:05 PM
0 · Reply
Hotresearchsgoldenage
Hotresearchsgoldenage Jun. 18 at 11:48 AM
$ABBV cures bladder cancer at 80 percent success rate. Meds ship in July 21,500!
0 · Reply
DonCorleone77
DonCorleone77 Jun. 18 at 11:22 AM
$ABBV AbbVie reports results from Phase 3 TEMPLE multicenter study AbbVie announced positive topline results from its Phase 3 TEMPLE multicenter, randomized, double-blind, head-to-head study evaluating the tolerability, safety and efficacy of atogepant, or QULIPTA/AQUIPTA, compared to the highest tolerated dose of topiramate in adult patients with a history of four or more migraine days per month. The study met the primary endpoint of treatment discontinuation due to adverse events, or AEs, demonstrating that atogepant, a calcitonin gene-related peptide, or CGRP, receptor antagonist, had fewer discontinuations due to AEs than topiramate, an anticonvulsant medication also approved for migraine prevention. Over the 24-week double-blind treatment period, discontinuation due to AEs was significantly lower with atogepant compared to topiramate, representing a relative risk of 0.41. The study also met all six secondary endpoints, including a key measure of clinical efficacy: 64.1% of patients on atogepant achieved a greater than or equal to50% reduction in mean monthly migraine days during months 4 to 6 of the double-blind treatment period compared to 39.3% of patients on topiramate. Migraine continues to be underdiagnosed and undertreated, despite significant burden on patients' lives. Full results from the TEMPLE study will be presented at an upcoming medical meeting.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jun. 18 at 11:20 AM
$ABBV AbbVie Announced Topline Results From Its Phase 3 TEMPLE Trial Of Atogepant Compared To The Highest Tolerated Dose Of Topiramate In Migraine Patients, The Study Met The Primary Endpoint
0 · Reply
ST4Life
ST4Life Jun. 18 at 2:16 AM
$ABBV Every few months, there are some bad news that lowers this stock, never fails.
0 · Reply
Dleadz
Dleadz Jun. 17 at 9:05 PM
0 · Reply
OnTheBalance
OnTheBalance Jun. 17 at 7:59 PM
$SLS Here are two visuals that are more powerful than any PR, both from MSK, If you don't get it, it doesn't matter because that's what BIG BP wants $MRK $BMY $ABBV $XBI
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jun. 17 at 6:01 PM
$SLS - Nice to Hear Angie using the word BLOCKBUSTER today. . . SLS Is the INVESTMENT Opportunity of a Lifetime. Recall ALL THE NAKED SHORT SELLING TO HOLD THE PRICE DOWN - ARTIFICIALLY MANIPULATING THE SHARE PRICE -- when the IDMC UNBLINDED the Actual Phase 3 Interim Overall Survival and Immune Response Trial Data, SLS share price doubled ... As the Unblinded Data, allowed (s) Institutional Investors, and Industry Players ($ABBV $BMY know exactly how Aza+Ven Performs compared to the not Yet Met Greater than >13.5 month, ALL Pooled P3 Data.) to Understand GPS is GOLDEN and SLS is worth a F TON MORE THAN what Shorts have sold the price down to.... NO HOLDERS ARE LETTING ANY GO, before the P3 Data, Just Short Manipulation and IDIOT LEMMING RETAIL.
0 · Reply